에서 실시간으로 운영 중이에요! 자세히 알아보기

Senseonics Holdings Inc

SENS

시가총액 US$4.11억

7.77 USD

-0.46

5.59%

장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT

프리마켓

시간외 거래

7.75

-0.02

0.26%

1일

-5.59%

5일

-13.38%

1개월

-14.24%

3개월

51.17%

6개월

14.77%

연초 이후

31.92%

1년

-8.26%

5년

-88.19%

10년

-88.4%

소개: Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.

직원 수: 130

건강관리 의료기기

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 12.5%

중립 75%

부정적 12.5%

Senseonics: Eversense 365 Adoption Has To Earn The Valuation

Senseonics is rated Hold due to positive sales growth, margin improvement, and product differentiation, but with significant adoption and funding risks. SENS's Eversense 365 offers unique implantable CGM technology, but recurring revenue depends on repeat implantations and overcoming barriers like prescriber adoption and insurance approvals. Q2 2026 saw 117.8% sales growth and gross margin improvement to 59.1%, but high SG&A expenses, ongoing dilution, and negative free cash flow persist.

Senseonics: Eversense 365 Adoption Has To Earn The Valuation

Zacks Investment Research

Beta Bionics Stock Down Despite iLet-Eversense 365 Integration Deal

BBNX's Eversense 365 partnership is likely to broaden CGM choice and strengthen its automated insulin delivery ecosystem across iLet and mint.

Beta Bionics Stock Down Despite iLet-Eversense 365 Integration Deal

Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas

Pairing year-long continuous glucose monitoring with automated insulin delivery to further simplify diabetes management for patients Brings Eversense 365 to the growing community of iLet Bionic Pancreas users Plan for commercial launch of the integrated system in Q4 2026 GERMANTOWN, Md., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), maker of the Eversense 365 Continuous Glucose Monitoring (CGM) System, the world's first and only long-term, one-year implantable sensing technology, today announced a partnership with Beta Bionics, Inc (NASDAQ: BBNX), a pioneering leader in the development of advanced diabetes management solutions.

Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas

Senseonics To Participate in Upcoming Institutional Investor Conferences

GERMANTOWN, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in two upcoming investor conferences.

Senseonics To Participate in Upcoming Institutional Investor Conferences

Senseonics Holdings, Inc. Common Stock Q2 Earnings Call Highlights

Senseonics Holdings, Inc. Common Stock NASDAQ: SENS raised its full-year 2026 revenue and gross-margin outlook after reporting second-quarter revenue growth of approximately 120% and its highest organic gross margin to date.

Senseonics Holdings, Inc. Common Stock Q2 Earnings Call Highlights

Senseonics Holdings, Inc. (SENS) Q2 2026 Earnings Call Transcript

Senseonics Holdings, Inc. (SENS) Q2 2026 Earnings Call Transcript

Senseonics Holdings, Inc. (SENS) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Senseonics Holdings (SENS) Reports Q2 Loss, Tops Revenue Estimates

Senseonics Holdings (SENS) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.4 per share a year ago.

Senseonics Holdings (SENS) Reports Q2 Loss, Tops Revenue Estimates

Senseonics Holdings, Inc. Schedules Second Quarter 2026 Earnings Release and Conference Call for August 6, 2026 at 4:30 P.M. Eastern Time

GERMANTOWN, Md., July 21, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, August 6, 2026.

Senseonics Holdings, Inc. Schedules Second Quarter 2026 Earnings Release and Conference Call for August 6, 2026 at 4:30 P.M. Eastern Time

Zacks Investment Research

Strength Seen in Senseonics (SENS): Can Its 6.1% Jump Turn into More Strength?

Senseonics (SENS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in Senseonics (SENS): Can Its 6.1% Jump Turn into More Strength?

Zacks Investment Research

Senseonics Expands Eversense 365 Ecosystem With Welldoc Partnership

SENS partners with Welldoc on a next-gen Eversense 365 app, adding Apple Health/Google Health Connect integration ahead of the U.S. launch.

Senseonics Expands Eversense 365 Ecosystem With Welldoc Partnership

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.